AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
AMN Healthcare Services (AMN) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $96.75, making no change from the previous trading session.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
Intuitive Surgical (ISRG) Falls Following Q4 Earnings Miss
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales and unfavorable currency. Procedure volume in China suffers.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
CVS Health (CVS) to Expand Health Care Access With New Pact
by Zacks Equity Research
CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.
QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow
by Zacks Equity Research
QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.
Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now
by Zacks Equity Research
Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.
Abbott's (ABT) New FDA Approval to Improve Patient Outcome
by Zacks Equity Research
Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots (WBA) continues to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels.
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
by Zacks Equity Research
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%
by Zacks Equity Research
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
Charles River (CRL) to Develop RNA-based Therapy With New Pact
by Zacks Equity Research
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues
by Zacks Equity Research
ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.
Down -8.76% in 4 Weeks, Here's Why You Should You Buy the Dip in AMN Healthcare (AMN)
by Zacks Equity Research
AMN Healthcare (AMN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays
by Zacks Equity Research
Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome
by Zacks Equity Research
Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.
AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $105.03, marking a +1.13% move from the previous day.
Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio
by Zacks Equity Research
The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement
by Zacks Equity Research
IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.